Head-to-head evidence
Halobetasol Propionate Foam vs Halobetasol Propionate Lotion
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: Glucocorticoid receptor · full Psoriasis pipeline
Halobetasol Propionate Foam · Lexette
Marketed by Mayne Pharma
NCT02742441 · Phase 3 · completed
The trial randomized 409 participants to active foam or vehicle foam and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was met, with treatment success in 30.7% versus 7.4% of participants at Day 15 (p<0.001).
Halobetasol Propionate Lotion · Bryhali
Marketed by Bausch Health
NCT02514577 · Phase 3 · completed
The study was randomized, quadruple-blinded, and vehicle-controlled, with 217 participants, and used a clinical Investigator’s Global Assessment endpoint. Although the reported Week 8 results favored halobetasol, the registry does not state whether the primary comparison was statistically significant, so the result remains unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Halobetasol Propionate Foam's landscape · Halobetasol Propionate Lotion's landscape